U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340216) titled 'Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis' on Dec. 19, 2025.
Brief Summary: This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
Study Start Date: Dec. 15, 2025
Study Type: INTERVENTIONAL
Condition:
Psoriasis
Intervention:
DRUG: ARQ-154 Foam 0.3%
ARQ-154 Foam 0.3%
Recruitment Status: RECRUITING
Sponsor: Arcutis Biotherapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....